Protalix BioTherapeutics (DE) (PLX) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Sionna Therapeutics (SION) over the past year, gaining 8.4% versus a loss of 83.2%. Protalix BioTherapeutics (DE) is the larger company by market cap ($218.3 million vs $217.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLX | SION |
|---|---|---|
| Share price | $2.71 | $4.82 |
| Market cap | $218.35M | $217.62M |
| 1-day change | -0.73% | +1.47% |
| YTD return | +50.56% | -88.28% |
| 1-year return | +8.40% | -83.15% |
| 5-year return | +120.33% | — |
| P/E ratio (TTM) | 11.78 | — |
| Forward P/E | 4.37 | — |
| EPS (TTM) | $0.23 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $54.97 |
| 52-week low | $1.60 | $4.01 |
| Distance from 52-week high | -15.05% | -91.23% |
| Analyst consensus | none | hold |
| Avg. price target upside | +305.90% | +335.68% |
| Average volume | 732.64K | 2.19M |
| Shares outstanding | 80.57M | 45.15M |
| Employees | 226 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed SION by 91.6 percentage points over the past year.
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
PLX vs SION FAQ
Which is bigger, Protalix BioTherapeutics (DE) or Sionna Therapeutics?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $218.35M compared with $217.62M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, PLX or SION?
PLX returned +8.40% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Protalix BioTherapeutics (DE) and Sionna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Protalix BioTherapeutics (DE) and Biotechnology: Pharmaceutical Preparations for Sionna Therapeutics.